Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (August 2020)

49 slides from Zynerba Pharmaceuticals's investor presentation, Aug 10, 2020

  1. Slide 1: Corporate Overview August 2020

    Corporate Overview August 2020

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements 2 © 2020 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE S

  3. Slide 3: A Rare/Near-Rare Neuropsychiatric Company

    Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near - Rare Neuropsychiatric Company • Deep pipeline focused on high unmet medical needs; translating into multi - billion dollar market opportunity with Zygel ™ (Cannabidiol Gel) • Currently pursuing four neuropsychiatric indications: • Fragile X synd

  4. Slide 4: Deep Clinical Pipeline

    Deep Clinical Pipeline 4 *Orphan Drug Designation Zygel Cannabidiol Gel Expected Milestones Discussions with FDA in 2H2020 to discuss pivotal results in FXS patients with full methylation D iscuss clinical path forward with FDA in 2H2020 Completion of enrollment once COVID - 19 restrictions in Austr

  5. Slide 5: Zygel (ZYN002) Cannabidiol Gel

    Neuropsych Indications Differentiated F ormulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 5 Unique Mechanism of Action First & only patent - protected (2038), permeation - enhanced, pharmaceutically - produced CBD gel Transdermal CBD m

  6. Slide 6: Fragile X Syndrome (FXS)

    Fragile X Syndrome (FXS) 6

  7. Slide 7: Fragile X Syndrome (FXS) Overview

    Fragile X Syndrome (FXS) Overview 7 • Rare genetic developmental disability • L eading known cause of both inherited intellectual disability and autism spectrum disorder • Symptoms linked to deficiencies in the endocannabinoid (EC) system • System of neurotransmitters regulates emotional responses,

  8. Slide 8: FMR1 gene and methylation in FXS

    8 • FMR1 gene codes for production of FMRP which is vital to synapse development • Mutation manifests as multiple repeats of a DNA segment (CGG) in FMR1 • No Fragile X: Segment repeats 5 to 40 times; normal production of FMRP • Premutation Fragile X: Segment repeats 50 to 200 times; reduced FMRP pro

  9. Slide 9: CONNECT-FX: A Pivotal Trial In FXS

    CONNECT - FX: A Pivotal Trial In FXS 9 C linical study O f Ca NN abidiol (CBD) in Childr E n and Adoles C en T s with F ragile X (CONNECT - FX) Zygel (n=110) 250 mg daily 500 mg daily (weight - based dose) Placebo (n=102) Mirrors Zygel administration Treatment 212 patients randomized Three through 1

  10. Slide 10: CONNECT-FX Baseline Characteristics

    10 CONNECT - FX Baseline Characteristics Placebo Zygel Total n 102 110 212 Age (years) 9.8 9.6 9.7 Sex – Males , n (%) 78 (76%) 81 (74%) 159 (75%) Weight (kg) Median 34.3 36.8 35.7 Range (Min, Max) 15.6, 104.7 14.6, 87.0 14.6, 104.7 >35kg, % 48% 56% 52% Baseline psychoactive medications, % 66% 57% 6

  11. Slide 11: CONNECT-FX: Qualitative Caregiver Reported Behavioral Survey

    11 CONNECT - FX: Qualitative Caregiver Reported Behavioral Survey Top 10 Classifications of Behavioral Challenges Utilizing the Qualitative Caregiver Reported Behavioral Survey, caregivers were asked to describe their most important behavioral challenges at baseline 66% 42% 33% 30% 29% 28% 26% 23% 2

  12. Slide 12: CONNECT-FX: A Pivotal Trial In FXS endpoints

    CONNECT - FX: A Pivotal Trial In FXS 12 • Primary endpoint: • Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale • Key secondary endpoints: • Change from baseline to end of the treatment in • ABC - C FXS Irritability subscale score • ABC - C FXS Socially Unresponsive/L

  13. Slide 13: CONNECT-FX: Rationale for Pre-Planned Ad Hoc Analysis

    13 • Methylation of genes is considered to be important in numerous pathological disorders including FXS • Methylation has been associated with the mechanism of mGluR5 in FXS • Currently, treatment options are limited for many of these disorders • The degree of methylation can influence the severity

  14. Slide 14: CONNECT-FX Patients: Full Data Set, FMet, Non-FMet

    CONNECT - FX 14 Patients Full Data Set FMet Group Non - FMet Group Randomization (ITT) 212 169 42 Full Analysis set 210 167 42 • One patient did not receive study medication after randomization and one patient did not have post - baseline efficacy assessments resulting in 210 patients in Full Analys

  15. Slide 15: Demographics and Baseline Characteristics: Full Data Set and FMet Group

    CONNECT - FX: Demographics and Baseline Characteristics 15 Similar in the Full Data Set and FMet Group Full Data Set Group FMet Group Placebo Zygel Total Placebo Zygel Total n 102 110 212 77 92 169 Age (years) 9.8 9.6 9.7 9.6 9.2 9.4 Sex – Males (%) 78 (76%) 81 (74%) 159 (75%) 54 (70%) 65 (71%) 119

  16. Slide 16: Pre-Planned Ad Hoc Results: FMet Group

    Pre - Planned Ad Hoc Results: Fmet Group 16 Zygel Achieved Statistical Significance on Social Avoidance: Changes From Baseline to Week 12 (ABC - C FXS ) Placebo N=76 Zygel N=91 Endpoints Baseline Mean ( SE) Week 12 Mean (SE) Week 12 Median Percent Change Baseline Mean ( SE) Week 12 Mean (SE) Week 12

  17. Slide 17: ABC-C FXS Social Avoidance Changes in FMet Group (Placebo)

    CONNECT - FX: A BC - C FXS Social Avoidance Changes From Baseline to Week 12 in FMet Group 17 In placebo group, the most common change (mode) in Social Avoidance was zero 0 2 4 6 8 10 12 14 16 18 20 22 24 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 Placebo (n=75) Number of patients Change from ba

  18. Slide 18: Zygel group demonstrated greater improvement versus placebo

    18 Zygel group demonstrated greater improvement versus placebo 0 2 4 6 8 10 12 14 16 18 20 22 24 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 Zygel (n=88) Placebo mode = 0 Zygel mode = −4 Nearly twice (1.9x) as many Zygel children experienced changes of 4 or more points relative to placebo (n=36 v

  19. Slide 19: Caregiver Global Impression - Change: FMet Group

    CONNECT - FX: Caregiver Global Impression - Change: FMet Group 0 10 20 30 40 50 60 70 Placebo Zygel Change from Baseline to Week 12: Broad Shifts Towards Global Improvement Placebo Zygel Placebo Zygel Placebo Zygel Overall Behavior Social Interactions Irritable and Disruptive Behaviors Social Avoida

  20. Slide 20: Zygel Advantages Observed in Social Avoidance Are Supported

    Zygel A dvantages O bserved in Social Avoidance Are Supported by Caregiver and Clinical Global Impression Improvements in FMet Group * Statistically significant ** Not specific to Social Avoidance 20 Primary Endpoint: ABC - C FXS Social Avoidance Subscale • Statistically significantly improvement vs

  21. Slide 21: CONNECT-FX: Safety

    CONNECT - FX: Safety Zygel Was Very Well Tolerated in FXS Patients 21 • Zygel was very well tolerated • Safety profile consistent with previously released data from all other Zygel trials • No safety signal identified • No serious or severe adverse events reported during the study • All treatment -

  22. Slide 22: Next Steps in Fragile X Program

    Next Steps in Fragile X Program 22 • Discuss CONNECT - FX data and the pathway for submitting a New Drug Application (NDA) with FDA • P ivotal data to be published and presented at upcoming medical meetings

  23. Slide 23: Autism Spectrum Disorder (ASD) in children and adolescents

    23 Autism Spectrum Disorder (ASD) in c hildren and adolescents

  24. Slide 24: ASD in Pediatrics Overview

    ASD in Pediatrics Overview 24 • Near - rare disorder affecting ~ 1MM pediatric and adolescent patients • Symptoms include • Irritability • Anxiety • Restricted, repetitive patterns of behavior • Impairments in social communication • Deficits in verbal and non - verbal communication • Deficits in dev

  25. Slide 25: Rationale for Developing Zygel in ASD

    Rationale for Developing Zygel in ASD 25 • Newer studies suggest ASD is linked to disruption in the EC system • Altered anandamide signaling may contribute to ASD - related social and communication impairments • EC system modulates many cellular functions and molecular pathways altered in ASD: imbal

  26. Slide 26: BRIGHT Phase 2 Trial in ASD

    BRIGHT Phase 2 Trial in ASD 26 Open - La B el Tole R ab I lity and Efficacy Study of ZYN002 Administered as a Transdermal G el to C H ildren and Adolescen T s with Autism Spectrum Disorder 37 patients enrolled Three through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: COMP

  27. Slide 27: Baseline Patient Population: BRIGHT

    Baseline Patient Population: BRIGHT Patients enrolled (n) 37 Included in safety analysis 37 Included in efficacy analyses 36* Discontinuations 9 Patients completing 14 - week trial 28 BRIGHT Trial Patient Populations 27 * One patient was lost to follow up and did not have post - dosing efficacy asse

  28. Slide 28: Baseline Patient Demographics

    Baseline Patient Demographics Patients enrolled, n 37 Age, years Mean (range ) 9.2 (3 - 16) Sex, n (%) Male Female 34 (91.9%) 3 (8.1%) Race, % White Asian Native Hawaiian or othe r Pacific Island Other 70.3% 8.1% 2.7% 18.9% Time to diagnosis, years 5.4 Underlying medication, % Subjects entering with

  29. Slide 29: Strong Safety and Tolerability Profile in BRIGHT Trial in ASD

    • W ell tolerated; consistent with previously released data • Fewer than half of patients experienced an adverse event (AE); most were mild and transient • Only 14% of patients experienced a treatment - related AE • All application site - related • No severe or serious AEs reported during the study.

  30. Slide 30: Percent Improvement in ABC-C Subscale Scores at Week 14

    30 0 5 10 15 20 25 30 35 40 45 Irritability Inappropriate Speech Stereotypy Social withdrawal Hyperactivity Baseline: 30.3 Baseline: 12.3 Baseline: 7.4 Baseline: 37.0 Baseline: 25.1 39.1% 42.5% 35.6% 36.4% 42.6% Mean % Improvement from Baseline 39.1% * Statistically significant p<0.0001* Statistical

  31. Slide 31: ABC-C Responses Supported by Other Efficacy Assessments

    Results of other efficacy assessments support the results demonstrated in the ABC - C, including: • Parent Rated Anxiety Scale - Autism Spectrum Disorder (PRAS - ASD): • M ean improvement of 46% at week 14 from baseline (p<0.0001) • Clinical Global Impression - Improvement (CGI - I ) • 57 % of patie

  32. Slide 32: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome ( 22q) 32

  33. Slide 33: 22q Overview

    22q Overview 33 • Most common contiguous gene deletion syndrome • Rare disorder: ~81K patients in US • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy • Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities

  34. Slide 34: 22q Patient Management

    22q Patient Management 34 • Two primary stages of 22q patient management: • During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery • Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety an

  35. Slide 35: Rationale for Developing Zygel in 22q

    Rationale for Developing Zygel in 22q 35 • CBD may treat neuropsychiatric symptoms in 22q due to activity as: • Modulator of endocannabinoid system • Agonist at serotonin 1A receptors • Antagonist at GPR55 receptors • Early control of anxiety may delay the development of psychosis • Phase 2 study un

  36. Slide 36: INSPIRE Phase 2 Trial in 22q

    INSPIRE Phase 2 Trial in 22q 36 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks 250 mg to 500 mg daily E fficacy assessments (week 14 vs baseline) include: • Aberrant Behavior Checklist - Community ( ABC - C) • Anxiety , Depression and Mood Scal

  37. Slide 37: DEE Developmental and Epileptic Encephalopathies

    DEE Developmental and Epileptic Encephalopathies 37

  38. Slide 38: DEE Patients are Medically Fragile

    DEE Patients are Medically Fragile 38 • G roup of rare / ultra rare childhood - onset epilepsies with impaired or regressed developmental progress • Cognitive impairment, psychiatric problems, and behavioral disturbances are phenotypic • Medically fragile population • Comorbidities include cerebral

  39. Slide 39: BELIEVE Phase 2 Trial in DEE

    BELIEVE Phase 2 Trial in DEE 39 Open La B el Study to Assess the Safety and E fficacy of ZYN002 Administered as a Transderma L Gel to Ch I ldren and Adol E scents with De V elopmental and E pileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titr

  40. Slide 40: BELIEVE: Clinically Meaningful Seizure Reductions

    40 BELIEVE: Clinically Meaningful Seizure Reductions from Baseline and Sustained through Six Months in DEE 0 10 20 30 40 50 60 70 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Median Percent Reduction from Baseline, FIAS and CS N=33 N=33 N=33 N=32 N=32 N=29 16% 44% 44% 47% 58% 51% Median Percent R

  41. Slide 41: BELIEVE: Patients with ≥35% and ≥50% Reduction in FIAS and TCS

    BELIEVE: Percentage of Patients with ≥35% and ≥50% Reduction in FIAS and TCS 41 Data reported at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session ≥35 % and ≥50 % Reduction in FIAS and TCS by Time Point , mITT Population With FIAS and/or TCS at Baseline (n = 33)

  42. Slide 42: BELIEVE Safety

    42 • All events in six month period, whether unrelated or related to study drug, reported as adverse AEs (e.g.: influenza, runny nose, scrapes , etc.) • As a result and as anticipated, most patients experienced an AE • Most were mild and transient • Only one patient discontinued due to an AE (applic

  43. Slide 43: BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements

    43 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale • Statistically significant reductions from baseline in subscale scores for seizure severity, behavior, and mood observed at month 6 (p<0.01) • Qualitative

  44. Slide 44: BELIEVE: Good Day/Bad Day

    44 BELIEVE: Qualitative Assessments of Behavioral and Cognitive Improvements • Good Day/Bad Day comparing baseline to month six: • “Good day” and “fantastic day” reports increased from 52% to 70% • “Terrible day” and “bad day” reports decreased from 12% to 4% Data reported at the 2020 American Acade

  45. Slide 45: Compelling Results Suggest a Potential Pathway to Pivotal Trials

    45 • Zynerba engaging with FDA on next clinical steps • Efficacy results: • Clinically meaningful reductions in seizures beginning in month two and sustained through six months • Suggest improvements on important behavioral symptoms • Safety results: • Zygel was well tolerated • Consistent with prev

  46. Slide 46: Planned Approach to FDA

    46 Syndromes and encephalopathies Dravet LGS West Early myoclonic epilepsy Hypoxic - ischemic e nceph . S eizure type Focal Impaired Awareness Bilateral Tonic Clonic Generalized Tonic Clonic Focal aware Absence Convulsive Other Seizure types Consciousness impairing seizures Doose Ohtahara Landau - K

  47. Slide 47: Financial Strength

    Financial Strength 47 • Clean balance sheet • No debt, 29.3 M shares outstanding (as of August 6, 2020) • Cash and cash equivalent position of $77.0M as of June 30, 2020 • Cash runway expected to be sufficient to fund operations and capital requirements i nto the fourth quarter of 2021

  48. Slide 48: Expected Clinical Milestones in 2020

    Expected Clinical Milestones in 2020 48 FXS DEE Report pivotal CONNECT - FX topline results ASD 22q 1Q 2020 2Q 2020 Report Ph. 2 BRIGHT topline results 3Q 2020 4Q 2020 Discuss clinical path forward in ASD with FDA Results of FDA discussions on clinical path Discuss results in fully - methylated FMR1

  49. Slide 49: Corporate Overview August 2020

    Corporate Overview August 2020

Zynerba Pharmaceuticals — Investor Presentation (August 2020) on 6ix